← Back to Search

Antiarrhythmic agents

Patients who didn't fail AAD for Ventricular Tachycardia (EPI-VT Trial)

Q: What is the desired outcome of this experiment?

This medical trial will assess the efficacy of its intervention by tracking Freedom from Documented VT Episodes over a 12-month period. Secondary objectives are Procedure Duration and Fluoroscopy Time, Incidence of Peri-procedural and Post-Procedural Complications (such as Ischemic <a href="https://www.withpower.com/clinical-trials/stroke">Stroke</a>, Cardiac Perforation, Rehospitalization or Death), as well as Long Term Follow Up to Gauge Freedom from Documented VT Episodes at 24 Months and 60 Months.

Q: Is geriatric participation allowed in this research study?

According to the criteria listed, individuals aged 18-99 are eligible for this clinical trial. There are also 27 studies available for minors and 249 trials appropriate for people over 65 years old.

Q: Is it possible for me to join this research project?

The requirements to partake in this medical experiment are tachycardia, ventricular arrhythmia and an age ranging from 18 to 99 years old. Around one hundred individuals will be involved.

Q: Is availability still offered to participants of this research endeavor?

Per the information hosted on clinicaltrials.gov, this particular medical trial is not currently looking for participants. Initially posted in May of 2021 and last updated in April 2022, it is one of 280 trials actively recruiting patients at present.

Phase < 1

Waitlist Available

Led By Jorge Romero, MD

Research Sponsored by Montefiore Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 and 60 months

Awards & highlights

EPI-VT Trial Summary

This trial will compare two ways of treating ventricular tachycardia (VT). The standard approach is to take drugs that help control the heart's rhythm. The other approach being studied is endocardial or endocardial-epicardial ablation, which is a procedure to destroy the tissue that is causing the VT. The goal is to see if the ablation procedure is more successful than the standard approach in treating VT over the long term.

Eligible Conditions

Ventricular Tachycardia

EPI-VT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 and 60 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 and 60 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 and 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Freedom from documented VT episodes

Freedom from documented VT episodes after second intervention

Secondary outcome measures

Cost-effectiveness analysis

Incidence of peri-procedural and 12-month post procedural complications

Long-term follow-up to evaluate freedom of documented VT episodes

+2 more

EPI-VT Trial Design

2Treatment groups

Active Control

Group I: Patients who didn't fail AADActive Control3 Interventions

This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications

Group II: Patients who failed AADActive Control2 Interventions

This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor

441 Previous Clinical Trials

582,196 Total Patients Enrolled

Jorge Romero, MDPrincipal InvestigatorMontefiore Medical Center/Albert Einstein College of Medicine

Luigi Di Biase, MDPrincipal InvestigatorMontefiore Medical Center/Albert Einstein College of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the desired outcome of this experiment?

"This medical trial will assess the efficacy of its intervention by tracking Freedom from Documented VT Episodes over a 12-month period. Secondary objectives are Procedure Duration and Fluoroscopy Time, Incidence of Peri-procedural and Post-Procedural Complications (such as Ischemic Stroke, Cardiac Perforation, Rehospitalization or Death), as well as Long Term Follow Up to Gauge Freedom from Documented VT Episodes at 24 Months and 60 Months."

Answered by AI

Is geriatric participation allowed in this research study?

"According to the criteria listed, individuals aged 18-99 are eligible for this clinical trial. There are also 27 studies available for minors and 249 trials appropriate for people over 65 years old."

Answered by AI

Is it possible for me to join this research project?

"The requirements to partake in this medical experiment are tachycardia, ventricular arrhythmia and an age ranging from 18 to 99 years old. Around one hundred individuals will be involved."

Answered by AI

Is availability still offered to participants of this research endeavor?

"Per the information hosted on clinicaltrials.gov, this particular medical trial is not currently looking for participants. Initially posted in May of 2021 and last updated in April 2022, it is one of 280 trials actively recruiting patients at present."

Answered by AI

Recent research and studies

JACC: Clinical ElectrophysiologyJournal

Combined Endocardial-epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease

Romero, Jorge, Roberto C. Cerrud-Rodriguez, Luigi Di Biase, Juan Carlos Diaz, Isabella Alviz, Vito Grupposo, Luis Cerna, et al.. 2019. “Combined Endocardial-epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease”. JACC: Clinical Electrophysiology. Elsevier BV. doi:10.1016/j.jacep.2018.08.010.

The American Journal of CardiologyJournal

Safety, Long-term Results, and Predictors of Recurrence After Complete Endocardial Ventricular Tachycardia Substrate Ablation in Patients with Previous Myocardial Infarction

Arenal, Ángel, Jesús Hernández, David Calvo, Cecilia Ceballos, Leonardo Atéa, Tomás Datino, Felipe Atienza, et al.. 2013. “Safety, Long-term Results, and Predictors of Recurrence After Complete Endocardial Ventricular Tachycardia Substrate Ablation in Patients with Previous Myocardial Infarction”. The American Journal of Cardiology. Elsevier BV. doi:10.1016/j.amjcard.2012.10.031.

CirculationJournal

Elimination of Local Abnormal Ventricular Activities

Jaïs, Pierre, Philippe Maury, Paul Khairy, Frédéric Sacher, Isabelle Nault, Yuki Komatsu, Mélèze Hocini, et al.. 2012. “Elimination of Local Abnormal Ventricular Activities”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/circulationaha.111.043216.

CirculationJournal